Tilray Brands, Inc. (TLRY)

In Q1 FY2026, Tilray reported strong results with a surprise net income, leading to a stock rally. Speculation on cannabis reclassification caused the stock to surge significantly in December 2025. Tilray completed a 1-for-10 reverse stock split in December 2025. In Q2 FY2026, Tilray reported record net revenue and moved to a net cash position, but the stock saw a slight dip. Tilray announced an exclusive multi-year licensing agreement with Carlsberg Group, leading to a stock increase. In Q3 FY2026, Tilray reported record net revenue but missed adjusted EPS expectations, resulting in a stock decline, though Roth Capital upgraded the stock to "Buy".

Demand for Tilray Brands' products exhibits seasonality across its different segments. Cannabis sales peak around April 20th and during the holiday season, with summer months also seeing increased demand. The craft beer market experiences seasonal demand swings influenced by tourism and weather. While the overall hemp market is projected to grow, summer months may see increased demand for hemp-based wellness products, while winter might shift preferences towards vapes or products with warming effects.

Tilray Brands, Inc. operates in the pharmaceuticals, cannabis, and brewing industries, with business segments including Cannabis Operations, Distribution Business, Beverage Alcohol Business, and Wellness Business. The company's major products and brands include cannabis products under brands such as Tilray and Aphria, alcoholic beverages with brands like Montauk Brewing and Shock Top, distribution services focused on cannabis and pharmaceutical products, and hemp-based health and wellness products under brands like Charlotte's Web and Manitoba Harvest.

Tilray Brands has a significant global presence with operations across Canada, the United States, Europe, Australia, New Zealand, and Latin America. The company has cultivation facilities in Germany, Portugal, and the United Kingdom and has expanded its medical cannabis distribution in Europe, securing licenses in Poland and Italy. Tilray is also strategically positioned for potential U.S. federal cannabis legalization, leveraging its existing craft beer distribution network.

Tilray is recognized as a leader in the Canadian cannabis market and a significant player in the European medical cannabis sector. Its diversification into craft beverages enhances its market presence, and the partnership with Carlsberg Group strengthens its beverage portfolio. However, historical financial performance and shareholder dilution have led to investor skepticism, reflected in its stock price decline. Analysts have mixed ratings, with some maintaining a "Hold" and others upgrading to "Buy" based on international business outperformance and potential regulatory changes.

Tilray Brands' ownership includes institutional, retail, and individual investors. Major institutional shareholders include Susquehanna International Group, Llp and Toroso Investments, LLC. Irwin D. Simon, the Chairman and CEO, owns a significant number of shares, and Brendan Kennedy owns 9.03 million shares, representing 7.75% of the company. Insiders collectively hold approximately 7.25% of the company's stock, while public companies and individual investors hold a substantial portion.